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Background: newborns and young infants suffer high rates of infections 
in South Asia and sub-Saharan Africa. timely access to appropriate anti-
biotic therapy is essential for reducing mortality. In an effort to develop 
community case management guidelines for young infants, 0–59 days old, 
with clinically diagnosed severe infections, or with fast breathing, 4 trials 
of simplified antibiotic therapy delivered in primary care clinics (pakistan, 
Democratic Republic of Congo, Kenya and nigeria) or at home (Bangla-
desh and nigeria) are being conducted.
Methods: this article describes the scientific rationale for these trials, 
which share major elements of trial design. All the trials are in settings of 
high neonatal mortality, where hospitalization is not feasible or frequently 
refused. All use procaine penicillin and gentamicin intramuscular injections 
for 7 days as reference therapy and compare this to various experimental 
arms utilizing comparatively simpler combination regimens with fewer 
injections and oral amoxicillin.
Conclusion: the results of these trials will inform World Health Organiza-
tion policy regarding community case management of young infants with 
clinical severe infections or with fast breathing.
Key Words: newborn, young infant, sepsis, pneumonia, meningitis, clini-
cally severe infections, fast breathing, community management, community 
case management, antibiotic, gentamicin, amoxicillin, procaine penicillin, 
South Asia, sub-Saharan Africa
(Pediatr Infect Dis J 2013;32:S7–S11)
Infections in the neonatal period are responsible for an estimated 12% of under-5 child mortality.1 most newborns with severe infec-
tions (sepsis, pneumonia, meningitis) in South Asia and sub-Saharan 
Africa die without access to hospitalization and appropriate therapy,2–6 
prompting the need for alternative strategies for home or first-level 
facility-based management in countries with a high burden of neo-
natal deaths.3–5,7 this article describes the scientific rationale for the 
study design of 3 randomized controlled equivalence trials evaluating 
simplified antibiotic regimens for management of clinically diagnosed 
severe infections in newborns and young infants in community settings 
in Bangladesh, pakistan and a multicountry study in Africa (Demo-
cratic Republic of Congo, Kenya and nigeria). Additionally, the sci-
entific reasoning underlying a trial of simplified antibiotic therapy for 
management of young infants who present with fast breathing alone 
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is also described. Although the individual study designs are adapted 
to site and country needs and are detailed in the site-specific meth-
ods articles,8–11 here we focus on the overarching scientific approach to 
case definitions, selection of trial sites, participant inclusion/exclusion 
criteria, choice of antibiotics and regimens and outcomes. the com-
mon design elements were made possible by extensive collaboration 
between the study sponsors12 and investigators and will enhance the 
interpretation and application of the studies’ results, in part by enabling 
future pooled analyses for outcomes of subgroups of interest (eg, treat-
ment failure in newborns with early-onset infections, newborns with 
multiple clinical signs of illness vs. single signs, etc.).
STUDY AGE GROUP
newborns have increased vulnerability to infection-related 
morbidity and mortality because of their immature immune systems 
and underdeveloped skin barrier.13 However, a decision to include 
infants beyond the newborn period, that is, in the second month of 
life, was made for 2 reasons. First, the newborn immune response 
matures on a gradient with age14 with increased susceptibility to 
infection persisting into the second month of life, and second, the 
current World Health Organization (WHO)/united nations Inter-
national Children’s emergency Fund Integrated management of 
Childhood Illness addresses children aged 0–59 days as a separate 
group (“young infants”) from children 2–59 months old.15 there-
fore, any new case management strategy for use in developing coun-
tries needs to be applicable to infants who are 0–59 days old.
DIAGNOSTIC ALGORITHM TO STANDARDIZE 
DEFINITION OF CLINICALLY DIAGNOSED SEVERE 
INFECTIONS IN NEWBORNS AND YOUNG 
INFANTS ACROSS THE TRIAL SITES
Infections in the newborn and young infant present with 
nonspecific signs and symptoms and can be difficult to diagnose 
even by experienced health professionals.13 A high index of sus-
picion and prompt initiation of antibiotic therapy are required to 
save lives because of the often rapidly fulminant course of invasive 
bacterial infections in young infants. this practice is followed in 
industrialized countries where clinically ill-appearing newborns 
and young infants are treated with parenteral antibiotics on the 
basis of a diagnosis of “presumed sepsis,” although blood cultures 
eventually are found to yield no growth in the vast majority.8,16–18
In an effort to promote the early detection and appropri-
ate referral of sick young infants by frontline health workers in 
resource-limited settings, WHO, united States Agency for Inter-
national Development and the Saving newborn lives Initiative of 
Save the Children (funded by the Bill and melinda Gates Founda-
tion) sponsored a multicountry study to evaluate several clinical 
signs for their utility in making referral decisions compared with 
the judgment of an experienced clinician.19 participating coun-
tries included Bangladesh, Bolivia, Ghana, India, pakistan and 
South Africa. the Young Infant Clinical Signs Study resulted in 
the development of a simple clinical algorithm based on 7 signs 
and symptoms for predicting severe illness in the young infant 
with high sensitivity and moderate specificity for use in first-level 
health facilities.19 the 7 clinical signs and symptoms are history 
of difficulty feeding, history of convulsions, movement only when 
stimulated, respiratory rate of 60 breaths per minute or more, severe 
chest indrawing, temperature of 37.5°C or more or less than 35.5°C. 
the presence of any one triggers a decision to refer the infant. the 
availability of the validated Young Infant Clinical Signs of Severe 
Illness algorithm presented an evidence-based starting point for the 
development of a clinical definition of severe infection in the young 
infant for use in the proposed trials. However, certain limitations of 
this algorithm influence specificity for the diagnosis of infection, 
considerations that are important in equivalence trial settings where 
a nonspecific definition of infection could dilute out important dif-
ferences in therapeutic options among a smaller group of infants 
who truly had severe bacterial infections included within a larger 
group of mildly ill infants who would recover without antibiotic 
therapy. In order to increase specificity of diagnosis of clinically 
diagnosed severe infection, the following modifications have been 
made: the fast respiratory rate sign has been dropped from our case 
definition as accumulating evidence indicates that it substantively 
reduces specificity of the case definition (see discussion below), 
the upper temperature cutoff (for fever) has been increased to 38°C 
(instead of 37.5°C) and history of difficulty feeding requires confir-
mation by observation of infant feeding (African sites) or determi-
nation of poor suck through digital examination if feeding cannot 
be observed (Asian sites). presence of convulsions is considered to 
indicate critical illness, and infants with convulsions are excluded. 
table 1 presents the case definition used for diagnosis of clinical 
severe infections in these trials.
Fast breathing (respiratory rate >60 per minutes) is frequently 
present as an isolated sign in young infants who do not otherwise appear 
ill.19 Fast breathing did not predict mortality in young infants in studies 
from Bangladesh and India.20–22 However, fast breathing even as a single 
sign is part of the WHO Integrated management of Childhood Illness 
clinical algorithm and indicates very severe disease and need for hospi-
tal referral and parenteral antibiotics.23 this has created a management 
dilemma, whether to treat young infants with fast breathing alone as 
a mild illness or as a severe illness. In some settings from South Asia, 
neonates and young infants with fast breathing have been successfully 
treated by oral antibiotics.6,24,25 there are no studies from Africa, and 
none have compared oral antibiotics with injectable therapy for man-
agement of infants with fast breathing as the only sign of illness. thus, 
there is a need to inform policy by providing evidence whether young 
infants with fast breathing alone can be treated with oral antibiotics. 
Such a study is being undertaken in the multicenter African sites.
TABLE 1. Comparison of WHO Integrated 
Management of Neonatal Child Illness Algorithm and 
Case Definition of Clinically Diagnosed Infection Used in 
the Young Infant Simplified Antibiotic Therapy Trials
WHO Integrated Management of  
Neonatal Child Illness Algorithm
Diagnostic Algorithm Used  
in Simplified Antibiotic 
Therapy Trials
Case Definition of Clinically 
Severe Infections (CSIs)
History of convulsions or convulsions —
Respiratory rate ≥60/min —
Severe chest indrawing Severe chest indrawing
Axillary temperature 37.5°C or  
above (>99.5°F or above)
Axillary temperature 
≥100.4°F (≥38.0°C)




Movement only when stimulated  
or no movement at all
Movement only with  
stimulation
Not feeding well Feeding difficulty, confirmed 
by feeding observation or 
documentation of poor suck 
on examination if mother 
unavailable (Asian sites)
Stopped feeding well/feed-
ing problems confirmed by 
observation of infant feed-
ing (African sites)
– indicates convulsions and fast respiratory rate are not included in the case defini-
tion of severe infection used in these trials.
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CHOICE OF ANTIBIOTICS, REGIMENS, DOSAGE, 
DURATION AND DELIVERY STRATEGIES
Ideally, the selection of an appropriate antimicrobial agent is 
based on its ability to kill bacteria that are responsible for the infection 
in the majority of cases, based on efficacy and safety data, and phar-
macokinetic information from relevant pediatric age groups.26 For the 
simplified antibiotic therapy trials, additional considerations include 
ease of delivery in community settings and cost—both factors with 
significant implications for future scale-up. the experimental arms, 
therefore, comprise combinations of injectable and oral antibiotics or 
switch therapy from injectable to oral antibiotics (tables 2 and 3).
penicillin and gentamicin are used globally for treating sep-
sis and presumed sepsis in the neonatal age group and the second 
month of life.15,27,28 extended-interval (24-hourly) gentamicin regi-
mens using doses ranging from 4 to 5 mg/kg/day have been shown 
to be as effective as traditional dosing regimens for treating neonatal 
sepsis.29–31 the combination of penicillin/amoxicillin and gentamicin 
targets common neonatal pathogens such as Escherichia coli, other 
enteric gram-negative rods, streptococci and pneumococci.
Benzyl penicillin and ampicillin need to be given 4 times a day, 
which is impractical in the outpatient setting. Based on recommenda-
tions from the 2007 london consultation on community-based strate-
gies for management of severe infections in young infants born in high 
mortality settings,12 the pharmacologic profile of antibiotics32,33 and 
experience of their use,3–5 we decided to use a combination of procaine 
penicillin and gentamicin delivered by intramuscular (Im) injection as 
the reference arm to treat clinically diagnosed severe infection because 
both can be given in once daily dosing and together can successfully 
treat vast majority of bacterial infections in young infants.
For the simplified experimental regimens, amoxicillin was 
selected as the oral agent. Oral antibiotics have successfully been 
used in community-based management of neonatal pneumonia, 
resulting in significant reduction in pneumonia and overall neo-
natal mortality.6,24 there is extensive experience with use of oral 
amoxicillin in newborns and young infants, and safety of this drug 
is well-established in this age group.27,34 In full-term neonates, the 
bioavailability of oral amoxicillin is high at approximately 80%.35 
Similar serum amoxicillin concentrations were achieved in neo-
nates in the first 4 days of life with intravenous and oral routes, 
with the exception of the first 30 minutes after dosing when levels 
were lower with oral administration.36,37
All the simplified experimental arms in these studies employ 
oral amoxicillin, yet in varying ways (table 2). Arm D (injection gen-
tamicin for 2 days and oral amoxicillin for 7 days) is being undertaken 
only in the African sites because of reservations by the technical 
Advisory Group about achieving an adequate sample size in pakistan 
and Bangladesh within the funding period. the study comparing ref-
erence therapy with oral amoxicillin alone in infants who have only 
fast breathing is also being conducted in African young infants.
Amoxicillin has been recommended for use in doses ranging 
from 50 to 150 mg/kg/day. Higher doses are recommended to achieve 
minimum inhibitory concentrations that can overcome pneumococ-
cal resistance. High-dose oral amoxicillin (80–90 mg/kg/day) is the 
therapy of choice for young children with otitis media and pneu-
monia due to suspected drug-resistant pneumococcal infection.38–40 
the recommended intravenous dose of amoxicillin for neonates in 
the first week of life is 100 mg/kg divided every 12 hours, whereas 
150 mg/kg/day divided every 8 hours is recommended for older neo-
nates.27 In the African and South Asian trials, amoxicillin is given 
in doses ranging from 80 to 100 mg/kg/day based on 1 of 6 weight 
bands in which the infant falls.
the duration of antibiotic therapy is based on achievement of 
cure for an infection. the WHO recommendation of 10 or more days 
duration of therapy for antibiotic treatment is not based on strong evi-
dence. Studies in Bangladesh and India have used 10 days of antibi-
otic therapy,4,5 whereas in pakistan, 7 days of procaine penicillin and 
gentamicin once daily was found to be effective in the management 
of possible serious bacterial infection in young infants when families 
refused referral care.3 Very severe pneumonia in older children has 
been treated with 7 days of injectable antibiotics with good results,41 
whereas severe pneumonia has been treated with 5 days of oral antibi-
otics.42 Switch therapy of injectable to oral antibiotics has been dem-
onstrated to be efficacious for treatment of serious infections in neo-
nates18 and in older children.43 For young infants with clinical severe 
infection included in this study, Im procaine penicillin will be used 
in a dose of 50,000 units/kg once daily Im and Im gentamicin in a 
4–7.5 mg/kg/day once daily dose Im (depending on weight band of 
the young infant). Duration of all regimens in this study will be 7 days.
the trials are designed to be open-label because of the diffi-
culty in ethically justifying use of placebo injections in the popula-
tion under study and because acceptability of simplified regimens 
with lower number of injections is an important secondary outcome 
for the trials.
SELECTION CRITERIA FOR TRIAL PARTICIPANTS 
AND TRIAL SITES
the current standard of care for young infants with clinical 
signs suggestive of severe infection is hospitalization and paren-
teral antibiotic therapy for 10 or more days.23 As discussed else-
where in this supplement44 and previously reported,4,45 this standard 
of care is rarely practiced in developing countries with high neona-
tal mortality rates. For ethical reasons, in the design of these trials, 
we felt compelled to only include sites where neonatal mortality 
rates and hospitalization refusal rates were known to be high,8–10 
and those young infants whose families refused referral advice for 
hospitalization for their sick young infants. Documented refusal of 
hospital admission thus forms an important inclusion criterion for 
enrolment of study subjects. the Bangladesh and pakistan inves-
tigators have reported their experience with family acceptance for 
TABLE 2. Antibiotics Regimens Evaluated in Trials 
of Simplified Antibiotic Therapy for Management of 
Newborns and Young Infants With Clinically Diagnosed 
Severe Infections (CSIs) or Fast Breathing
Reference arm
 A – Daily injection procaine penicillin and gentamicin for 7 days.
Experimental arms
 Clinically severe infections
   B –  Oral amoxicillin twice daily and once daily injection gen-
tamicin for 7 days.
   C –  Daily injection gentamicin and procaine penicillin for 2 days, 
followed by twice daily oral amoxicillin for additional 5 days.
   D –  Daily injection gentamicin and twice daily oral amoxicillin  
for 2 days, followed by oral amoxicillin for additional 5 days  
(African sites only).
 Fast breathing only
  E – Oral amoxicillin twice daily for 7 days.
TABLE 3. Number of of Intramuscular (IM) Injections in 
Each Therapeutic Arm
Arm A Arm B Arm C Arm D Arm E
14 7 4 2 0
Arm A: IM procaine penicillin and IM gentamicin for 7 days; Arm B: oral amoxicil-
lin and IM gentamicin for 7 days; Arm C: IM procaine penicillin and IM gentamicin 
for 2 days followed by oral amoxicillin; Arm D: oral amoxicillin and IM gentamicin for 
2 days followed by oral amoxicillin; Arm E: oral amoxicillin alone in infants with only 
fast breathing.
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hospitalization.22,45 Other site characteristics are reported in the 
site-specific articles in this supplement. the African trial sites in 
Democratic Republic of Congo, Kenya and nigeria were chosen 
to be broadly representative of central, eastern and western sub-
Saharan African countries with neonatal mortality rates exceeding 
40 per 1000 live births and remote locations making access to hos-
pital facilities difficult for many families.2
Despite the effect on study generalizability, we are exclud-
ing young infants with clinical signs of critical illness (unconscious, 
convulsions, apnea, unable to feed, unable to cry, cyanosed, bulg-
ing fontanelle, persistent vomiting), infants with weight less than 
1500 g and infants with surgical comorbidities because we cannot 
ethically justify random allocation of such infants to therapeutic 
options with oral antibiotics.
SELECTION OF PRIMARY STUDY OUTCOME
treatment failure on or before 7 days of therapy has been 
chosen as the primary study outcome in these trials and defined 
as a composite of death, clinical deterioration, serious adverse 
event, hospitalization or persistence of clinical signs beyond speci-
fied days. Death, although a hard outcome, has not by itself been 
selected as a primary outcome because we expect the number of 
deaths to be low (around 2%) based on prior experience3 as rescue 
therapy is going to be provided and it will be unethical to withhold 
such therapy. therefore, using the comparatively rare outcome of 
death will inflate the sample size to unfeasible levels. Because of 
the subjective nature of clinical signs of deterioration, their defini-
tions and determination have been standardized across sites and are 
described further in the site-specific articles.8–10
CONCLUSION
this article describes the scientific rationale for the study 
designs of 3 trials of simplified antibiotic therapy for the manage-
ment of clinically diagnosed severe infections and a trial of man-
agement of fast breathing in newborns and young infants currently 
being conducted in Bangladesh, pakistan, Democratic Republic of 
Congo, Kenya and nigeria. Although designed as independent stud-
ies, extensive collaboration between study sponsors and among study 
investigators has resulted in harmonization of study protocols wher-
ever possible, which will allow subsequent pooled analyses by pro-
viding sufficient power to address important policy questions regard-
ing outcomes in subgroups such as newborns with early-onset sepsis, 
and infants with multiple clinical signs (indicating more severe ill-
ness) versus single signs. these trials will inform the development 
of policies and guidelines regarding community case management of 
newborns and young infants with clinically diagnosed severe infec-
tions as well as for infants with fast breathing alone.
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